Propelled by a flurry of dealmaking late in the year, 2025 M&A ended on a strong note, with high activity expected to ...

Novartis and Relation's target discovery deal falls under Novartis’ wider ploy to strengthen its immunology portfolio.

The framework has had a lukewarm reaction, with trade association EFPIA saying the policies are “not strong enough”.

China’s National Medical Products Administration (NMPA) has granted approval for Sanofi’s rare haematologic disease ...

Pfizer is set to cut several jobs in Switzerland as part of a multi-year effort to lower expenses, as reported by Bloomberg.

Moderna is seeking to enhance some of its drugs with Nanexa’s technology as the biologics sector moves to less frequent ...

China’s NMPA has granted approval for Boehringer Ingelheim’s Jascayd (nerandomilast) to treat progressive pulmonary fibrosis ...

Formation Bio has acquired the global rights, excluding in Greater China, to LNK01006 from Lynk Pharmaceuticals.

The Alabama facility is part of the $27bn investment Eli Lilly has pledged to expand its US footprint. American ...

Formycon and Zydus Lifesciences have entered into an exclusive licensing and supply agreement for FYB206 in the US and Canada ...

The UK's 14.5% drug rebate reduction may help to quell souring pharma sentiments, which stem from the nation's low spending on innovative drugs.

This comes just under a month after Pfizer finalised a deal to acquire Metsera following a bidding war with Novo Nordisk.